P21
Ciliary neurotrophic factor (CNTF)-derived neurogenic peptide (adamantylated small-peptide derivative)
P21 (P021) is a small peptidergic compound derived from an active region of ciliary neurotrophic factor (CNTF), chemically modified (adamantylation) for stability and brain penetration. In preclinical models it is reported to enhance neurogenesis and BDNF signaling and to reduce tau pathology. It is preclinical/research-only.
Mechanism under study
Modeled on a CNTF peptide mimetic, P021 is reported to promote adult hippocampal neurogenesis, increase brain-derived neurotrophic factor (BDNF) signaling, and inhibit leukemia inhibitory factor signaling and abnormal tau hyperphosphorylation in rodent models of neurodegeneration.
Research-reported dosing
No human dosing exists. Rodent studies administer it orally (including in diet) or by injection at milligram-per-kilogram levels; there is no validated human protocol. Preclinical/research-only; not approved.
P21 is a small modified peptide studied mostly by oral/dietary and injectable routes in animals; it is not a standard water-reconstituted U-100 injectable in humans. Research handling follows the compound's solubility rather than a fixed bacteriostatic-water mix.
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
P21 FAQ
What is P21?
P21 (P021) is a small peptidergic compound derived from an active region of ciliary neurotrophic factor (CNTF), chemically modified (adamantylation) for stability and brain penetration. In preclinical models it is reported to enhance neurogenesis and BDNF signaling and to reduce tau pathology. It is preclinical/research-only.
What is the half-life of P21?
Not established in humans; designed for oral bioavailability and blood-brain-barrier penetration in animal studies. Human pharmacokinetics are unpublished.
What is the research-reported dosing for P21?
No human dosing exists. Rodent studies administer it orally (including in diet) or by injection at milligram-per-kilogram levels; there is no validated human protocol. Preclinical/research-only; not approved.
How is P21 reconstituted?
P21 is a small modified peptide studied mostly by oral/dietary and injectable routes in animals; it is not a standard water-reconstituted U-100 injectable in humans. Research handling follows the compound's solubility rather than a fixed bacteriostatic-water mix.
Is P21 FDA-approved?
No — P21 is not FDA-approved and is sold for laboratory research use only.
References
Related peptides
Dihexa
Angiotensin IV-derived oligopeptide analog (HGF/c-Met potentiator)
Dihexa is a small angiotensin IV-derived peptide analog developed as a candidate for cognitive disorders. In preclinical work it is reported to potentiate hepatocyte growth factor (HGF) signaling at the c-Met receptor and to promote synaptogenesis. Human data are essentially absent; it is preclinical/research-only.
Cerebrolysin
Porcine brain-derived neuropeptide preparation
A neurotrophic preparation of low-molecular-weight peptides and amino acids derived from porcine brain tissue, used in several countries for neurological conditions but not FDA-approved.
Semax
Synthetic ACTH(4-10) fragment analog
A synthetic peptide derived from a fragment of ACTH, developed in Russia and studied for nootropic and neuroprotective effects, typically administered intranasally in research.
Selank
Synthetic heptapeptide (tuftsin analog)
A synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia and studied for anxiolytic (anti-anxiety) and cognitive effects, often administered intranasally in research.